Recon: CSL to invest $1.5B on US drug production; FDA approves Arrowhead’s Redemplo for rare genetic disorder
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States